title: Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis.
abstract: OBJECTIVE
  The examination of HCV virological clearance through several randomized clinical trials of telaprevir in genotype 1 chronic hepatitis C.
  
  
  METHODS
  We analyzed the effect of telaprevir on the end of treatment virological response and the sustained response, and investigated its harmful effect using meta-analysis of 5 randomized controlled trials.
  
  
  RESULTS
  Overall analysis revealed a significant effect of telaprevir in both naive patients (RR, 1.32; 95% CI, 1.08-1.60) and previously failed treated patients (p<0.0001). Monotherapy and double therapy seemed to show no effect in naive patients. Triple therapy followed with PegIFN-2a plus ribavirin seemed to be effective in both naive patients and previously failed treated patients. Telaprevir was associated with a significantly higher incidence of serious adverse events (RR, 1.45; 95% CI, 1.00-2.10) and with discontinuation (RR, 2.23; 95% CI, 1.40-3.55) because of adverse events. In naive patients, relapsers and non-responders, the regimen of telaprevir/ PegIFN-2a/ribavirin for 12 weeks followed by PegIFN-2a/ribavirin for 12 weeks (T12PR24) was the optimal regimen regarding to efficiency and duration.
  
  
  CONCLUSIONS
  Telaprevir combined with PegIFN-2a plus ribavirin may improve sustained response in genotype 1 chronic hepatitis C. Regimen T12PR24 may be the best regimen in this respect. New randomized controlled trials are required to confirm this meta-analysis.
authors.affiliation: The Department of Infectious Diseases, Xian Jiaotong University, Xian, China. dang212@126.com
authors.forename: Shuang-Suo
authors.initials: SS
authors.lastname: Dang
authors.forename: Wen-Jun
authors.initials: WJ
authors.lastname: Wang
authors.forename: Xiu-Fang
authors.initials: XF
authors.lastname: Wang
authors.forename: Ya-Ping
authors.initials: YP
authors.lastname: Li
authors.forename: Mei
authors.initials: M
authors.lastname: Li
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Jia
authors.forename: Yuan
authors.initials: Y
authors.lastname: Wang
authors.forename: Enqi
authors.initials: E
authors.lastname: Liu
authors.forename: Sihai
authors.initials: S
authors.lastname: Zhao
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000178:diet therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C100416:peginterferon alfa-2a